Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 129

1.

N-terminus of pro-EMAP II regulates its binding with C-terminus, Arginyl-tRNA Synthetase, and Neurofilament light protein.

Xu H, Malinin NL, Awasthi N, Schwarz RE, Schwarz MA.

J Biol Chem. 2015 Feb 27. pii: jbc.M114.630533. [Epub ahead of print]

2.

Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.

Awasthi N, Hinz S, Brekken RA, Schwarz MA, Schwarz RE.

Cancer Lett. 2015 Mar 1;358(1):59-66. doi: 10.1016/j.canlet.2014.12.027. Epub 2014 Dec 16.

PMID:
25527450
3.

Blockade of EMAP II protects cardiac function after chronic myocardial infarction by inducing angiogenesis.

Yuan C, Yan L, Solanki P, Vatner SF, Vatner DE, Schwarz MA.

J Mol Cell Cardiol. 2015 Feb;79:224-31. doi: 10.1016/j.yjmcc.2014.11.021. Epub 2014 Nov 29.

PMID:
25456857
4.

Cadmium exposure from food: the German LExUKon project.

Schwarz MA, Lindtner O, Blume K, Heinemeyer G, Schneider K.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2014;31(6):1038-51. doi: 10.1080/19440049.2014.905711. Epub 2014 Apr 29.

PMID:
24645975
5.

Lead exposure from food: the German LExUKon project.

Schneider K, Schwarz MA, Lindtner O, Blume K, Heinemeyer G.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2014;31(6):1052-63. doi: 10.1080/19440049.2014.905875. Epub 2014 May 2.

PMID:
24645773
6.

Vascular mediators in chronic lung disease of infancy: role of endothelial monocyte activating polypeptide II (EMAP II).

Lal CV, Schwarz MA.

Birth Defects Res A Clin Mol Teratol. 2014 Mar;100(3):180-8. doi: 10.1002/bdra.23234. Epub 2014 Mar 12. Review.

7.

Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.

Awasthi N, Zhang C, Schwarz AM, Hinz S, Schwarz MA, Schwarz RE.

Mol Cancer Ther. 2014 May;13(5):1032-43. doi: 10.1158/1535-7163.MCT-13-0361. Epub 2014 Mar 7.

PMID:
24608575
8.

Semipolar polycyclic aromatic compounds: identification of 15 priority substances and the need for regulatory steps under REACH regulation.

Schwarz MA, Behnke A, Brandt M, Eisenträger A, Hassauer M, Kalberlah F, Seidel A.

Integr Environ Assess Manag. 2014 Jul;10(3):415-28. doi: 10.1002/ieam.1526. Epub 2014 Mar 20.

PMID:
24449130
9.

Dioxin and dl-PCB exposure from food: the German LExUKon project.

Schwarz MA, Lindtner O, Blume K, Heinemeyer G, Schneider K.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2014 Apr;31(4):688-702. doi: 10.1080/19440049.2013.878041. Epub 2014 Feb 26.

PMID:
24405321
10.

Definition of K(trans) and FA thresholds for better assessment of experimental glioma using high-field MRI: a feasibility study.

Engelhorn T, Schwarz MA, Hess A, Budinsky L, Pitann P, Eyüpoglu I, Doerfler A.

Clin Neuroradiol. 2014 Dec;24(4):337-45. doi: 10.1007/s00062-013-0257-3. Epub 2013 Dec 18.

PMID:
24346229
11.

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.

Zhang CΗ, Awasthi N, Schwarz MA, Schwarz RE.

Int J Oncol. 2013 Nov;43(5):1627-35. doi: 10.3892/ijo.2013.2099. Epub 2013 Sep 13.

12.

Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.

Awasthi N, Zhang C, Schwarz AM, Hinz S, Wang C, Williams NS, Schwarz MA, Schwarz RE.

Carcinogenesis. 2013 Oct;34(10):2361-9. doi: 10.1093/carcin/bgt227. Epub 2013 Jun 26.

13.

Ephrin-B2 reverse signaling increases α5β1 integrin-mediated fibronectin deposition and reduces distal lung compliance.

Bennett KM, Afanador MD, Lal CV, Xu H, Persad E, Legan SK, Chenaux G, Dellinger M, Savani RC, Dravis C, Henkemeyer M, Schwarz MA.

Am J Respir Cell Mol Biol. 2013 Oct;49(4):680-7. doi: 10.1165/rcmb.2013-0002OC.

14.

Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.

Awasthi N, Zhang C, Hinz S, Schwarz MA, Schwarz RE.

J Exp Clin Cancer Res. 2013 Mar 6;32:12. doi: 10.1186/1756-9966-32-12.

15.

MRI assessment of experimental gliomas using 17.6 T.

Schwarz MA, Pham M, Helluy X, Doerfler A, Engelhorn T.

Neuroradiology. 2013 Jun;55(6):709-18. doi: 10.1007/s00234-013-1149-6. Epub 2013 Mar 10.

PMID:
23475161
16.

Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.

Zhang C, Awasthi N, Schwarz MA, Hinz S, Schwarz RE.

PLoS One. 2013;8(2):e58037. doi: 10.1371/journal.pone.0058037. Epub 2013 Feb 27.

17.

Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer.

Zhang C, Awasthi N, Schwarz MA, Schwarz RE.

J Surg Res. 2013 Jun 15;182(2):227-34. doi: 10.1016/j.jss.2012.10.052. Epub 2012 Nov 15.

PMID:
23201270
18.

The heart beat does not make us tick: the impacts of heart rate and arousal on time perception.

Schwarz MA, Winkler I, Sedlmeier P.

Atten Percept Psychophys. 2013 Jan;75(1):182-93. doi: 10.3758/s13414-012-0387-8.

PMID:
23143915
19.

BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.

Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE.

Mol Cancer Ther. 2012 Dec;11(12):2644-53. doi: 10.1158/1535-7163.MCT-12-0447. Epub 2012 Oct 9.

20.

Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.

Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE.

PLoS One. 2012;7(6):e38477. doi: 10.1371/journal.pone.0038477. Epub 2012 Jun 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk